Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Reconciling Human-Canine Differences in Oral Bioavailability: Looking beyond the Biopharmaceutics Classification System.

Martinez MN, El-Kattan A, Awji E, Papich M.

AAPS J. 2019 Aug 8;21(5):99. doi: 10.1208/s12248-019-0364-4.

PMID:
31396733
2.

Effect of exogenous progesterone treatment on ovarian steroid hormones and oxidant and antioxidant biomarkers during peak and low breeding seasons in dromedary she-camel.

El-Maaty AMA, Mohamed RH, Hozyen HF, El-Kattan AM, Mahmoud MA, Ali AH.

Vet World. 2019;12(4):542-550. doi: 10.14202/vetworld.2019.542-550. Epub 2019 Apr 17.

3.

Targeting host metabolism by inhibition of acetyl-Coenzyme A carboxylase reduces flavivirus infection in mouse models.

Jiménez de Oya N, Esler WP, Huard K, El-Kattan AF, Karamanlidis G, Blázquez AB, Ramos-Ibeas P, Escribano-Romero E, Louloudes-Lázaro A, Casas J, Sobrino F, Hoehn K, James DE, Gutiérrez-Adán A, Saiz JC, Martín-Acebes MA.

Emerg Microbes Infect. 2019;8(1):624-636. doi: 10.1080/22221751.2019.1604084.

4.

Facial analysis using a new clinical device: The Kattan Facio-meter.

El Kattan ES, Elhiny OA, El Kattan ME, El Kattan AE, Elsheikh A.

J Clin Exp Dent. 2019 Jan 1;11(1):e9-e14. doi: 10.4317/jced.55394. eCollection 2019 Jan.

5.

Delineating the role of cooperativity in the design of potent PROTACs for BTK.

Zorba A, Nguyen C, Xu Y, Starr J, Borzilleri K, Smith J, Zhu H, Farley KA, Ding W, Schiemer J, Feng X, Chang JS, Uccello DP, Young JA, Garcia-Irrizary CN, Czabaniuk L, Schuff B, Oliver R, Montgomery J, Hayward MM, Coe J, Chen J, Niosi M, Luthra S, Shah JC, El-Kattan A, Qiu X, West GM, Noe MC, Shanmugasundaram V, Gilbert AM, Brown MF, Calabrese MF.

Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7285-E7292. doi: 10.1073/pnas.1803662115. Epub 2018 Jul 16.

6.

2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.

Dow RL, Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Cortes C, El-Kattan AF, Ford K, Freeman GB, Guimarães CRW, Liu S, Niosi M, Skoura A, Tess D.

J Med Chem. 2018 Apr 12;61(7):3114-3125. doi: 10.1021/acs.jmedchem.8b00152. Epub 2018 Apr 3.

PMID:
29570292
7.

Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System.

El-Kattan AF, Varma MVS.

Drug Metab Dispos. 2018 May;46(5):729-739. doi: 10.1124/dmd.117.080044. Epub 2018 Mar 1. Review.

PMID:
29496721
8.

A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects.

Li R, Niosi M, Johnson N, Tess DA, Kimoto E, Lin J, Yang X, Riccardi KA, Ryu S, El-Kattan AF, Maurer TS, Tremaine LM, Di L.

Drug Metab Dispos. 2018 Apr;46(4):346-356. doi: 10.1124/dmd.117.078790. Epub 2018 Jan 12. Erratum in: Drug Metab Dispos. 2018 Apr;46(4):483. Drug Metab Dispos. 2019 Mar;47(3):269.

PMID:
29330218
9.

Molecular properties associated with transporter-mediated drug disposition.

Varma MV, Lai Y, El-Kattan AF.

Adv Drug Deliv Rev. 2017 Jul 1;116:92-99. doi: 10.1016/j.addr.2017.05.014. Epub 2017 May 26. Review.

PMID:
28554577
10.

Extended Clearance Classification System (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters.

Varma MV, El-Kattan AF, Feng B, Steyn SJ, Maurer TS, Scott DO, Rodrigues AD, Tremaine LM.

Clin Pharmacol Ther. 2017 Jul;102(1):33-36. doi: 10.1002/cpt.595. Epub 2017 Feb 3. No abstract available.

PMID:
27984654
11.

Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System.

El-Kattan AF, Varma MV, Steyn SJ, Scott DO, Maurer TS, Bergman A.

Pharm Res. 2016 Dec;33(12):3021-3030. Epub 2016 Sep 12.

PMID:
27620173
12.

Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.

Varma MV, Kimoto E, Scialis R, Bi Y, Lin J, Eng H, Kalgutkar AS, El-Kattan AF, Rodrigues AD, Tremaine LM.

Clin Pharmacol Ther. 2017 Mar;101(3):406-415. doi: 10.1002/cpt.520. Epub 2016 Nov 18.

PMID:
27648490
14.

Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.

Varma MV, El-Kattan AF.

J Clin Pharmacol. 2016 Jul;56 Suppl 7:S99-S109. doi: 10.1002/jcph.695. Review.

PMID:
27385183
15.

Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development.

Cheng Y, El-Kattan A, Zhang Y, Ray AS, Lai Y.

Chem Res Toxicol. 2016 Apr 18;29(4):545-63. doi: 10.1021/acs.chemrestox.5b00511. Epub 2016 Mar 8. Review.

PMID:
26889774
16.

Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.

Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Carlo AA, Conrad R, Cortes C, Dow RL, Dowling MS, El-Kattan A, Ford K, Guimarães CR, Hepworth D, Jiao W, LaPerle J, Liu S, Londregan A, Loria PM, Mathiowetz AM, Munchhof M, Orr ST, Petersen DN, Price DA, Skoura A, Smith AC, Wang J.

ACS Med Chem Lett. 2015 Oct 6;6(11):1128-33. doi: 10.1021/acsmedchemlett.5b00215. eCollection 2015 Nov 12.

17.

Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Varma MV, Steyn SJ, Allerton C, El-Kattan AF.

Pharm Res. 2015 Dec;32(12):3785-802. doi: 10.1007/s11095-015-1749-4. Epub 2015 Jul 9.

PMID:
26155985
18.

Development and validation of an UPLC-MS/MS assay for quantitative analysis of the ghrelin receptor inverse agonist PF-5190457 in human or rat plasma and rat brain.

Ghareeb M, Leggio L, El-Kattan A, Akhlaghi F.

Anal Bioanal Chem. 2015 Jul;407(19):5603-13. doi: 10.1007/s00216-015-8730-2. Epub 2015 May 7.

19.

Strategies for skeletal muscle targeting in drug discovery.

Ebner DC, Bialek P, El-Kattan AF, Ambler CM, Tu M.

Curr Pharm Des. 2015;21(10):1327-36. Review.

PMID:
25269560
20.

Quantitative prediction of renal transporter-mediated clinical drug-drug interactions.

Feng B, Hurst S, Lu Y, Varma MV, Rotter CJ, El-Kattan A, Lockwood P, Corrigan B.

Mol Pharm. 2013 Nov 4;10(11):4207-15. doi: 10.1021/mp400295c. Epub 2013 Oct 10.

PMID:
24066726
21.

Intestinal targeting of drugs: rational design approaches and challenges.

Filipski KJ, Varma MV, El-Kattan AF, Ambler CM, Ruggeri RB, Goosen TC, Cameron KO.

Curr Top Med Chem. 2013;13(7):776-802. Review.

PMID:
23578023
22.

Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs.

Nkansah P, Antipas A, Lu Y, Varma M, Rotter C, Rago B, El-Kattan A, Taylor G, Rubio M, Litchfield J.

J Control Release. 2013 Jul 10;169(1-2):150-61. doi: 10.1016/j.jconrel.2013.03.032. Epub 2013 Apr 6.

PMID:
23570985
23.

Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.

Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, El-Kattan AF, Goosen TC, Lai Y.

Drug Metab Dispos. 2013 May;41(5):966-74. doi: 10.1124/dmd.112.050583. Epub 2013 Feb 7.

PMID:
23393219
24.

Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.

Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, Lin J, Varma MV.

Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):459-72. doi: 10.1517/17425255.2013.759210. Epub 2013 Jan 21. Review.

PMID:
23331046
25.

Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.

Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V.

Pharm Res. 2013 Apr;30(4):1188-99. doi: 10.1007/s11095-012-0956-5. Epub 2013 Jan 10.

PMID:
23307347
26.

Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes.

Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, Sugiyama Y, Lai Y.

Mol Pharm. 2012 Dec 3;9(12):3535-42. doi: 10.1021/mp300379q. Epub 2012 Nov 2.

PMID:
23082789
27.

Renal transporters in drug disposition, drug-drug interactions, and nephrotoxicity.

Feng B, El-Kattan AF, Radi ZA.

Curr Protoc Toxicol. 2012 Aug;Chapter 23:Unit 23.3.1-15. doi: 10.1002/0471140856.tx2303s53.

PMID:
22896010
28.

Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion.

Varma MV, Chang G, Lai Y, Feng B, El-Kattan AF, Litchfield J, Goosen TC.

Drug Metab Dispos. 2012 Aug;40(8):1527-37. doi: 10.1124/dmd.112.044628. Epub 2012 May 11.

PMID:
22580868
29.

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.

Lai Y, Varma M, Feng B, Stephens JC, Kimoto E, El-Kattan A, Ichikawa K, Kikkawa H, Ono C, Suzuki A, Suzuki M, Yamamoto Y, Tremaine L.

Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):723-43. doi: 10.1517/17425255.2012.678048. Epub 2012 Apr 18. Review.

PMID:
22509796
30.

pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.

Varma MV, Gardner I, Steyn SJ, Nkansah P, Rotter CJ, Whitney-Pickett C, Zhang H, Di L, Cram M, Fenner KS, El-Kattan AF.

Mol Pharm. 2012 May 7;9(5):1199-212. doi: 10.1021/mp2004912. Epub 2012 Apr 26.

PMID:
22489626
31.

In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation.

Bi YA, Kimoto E, Sevidal S, Jones HM, Barton HA, Kempshall S, Whalen KM, Zhang H, Ji C, Fenner KS, El-Kattan AF, Lai Y.

Drug Metab Dispos. 2012 Jun;40(6):1085-92. doi: 10.1124/dmd.111.043489. Epub 2012 Mar 1. Review.

PMID:
22381335
32.

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, Fenner KS.

Drug Metab Dispos. 2012 May;40(5):1007-17. doi: 10.1124/dmd.111.042994. Epub 2012 Feb 16.

PMID:
22344703
33.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, Pettersen J, Minich ML, Filipski KJ, Jones CS, Tu M, Aspnes G, Risley H, Bian J, Stevens BD, Bourassa P, D'Aquila T, Baker L, Barucci N, Robertson AS, Bourbonais F, Derksen DR, Macdougall M, Cabrera O, Chen J, Lapworth AL, Landro JA, Zavadoski WJ, Atkinson K, Haddish-Berhane N, Tan B, Yao L, Kosa RE, Varma MV, Feng B, Duignan DB, El-Kattan A, Murdande S, Liu S, Ammirati M, Knafels J, Dasilva-Jardine P, Sweet L, Liras S, Rolph TP.

J Med Chem. 2012 Feb 9;55(3):1318-33. doi: 10.1021/jm2014887. Epub 2012 Jan 24.

PMID:
22196621
34.

Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes.

Kimoto E, Walsky R, Zhang H, Bi YA, Whalen KM, Yang YS, Linder C, Xiao Y, Iseki K, Fenner KS, El-Kattan AF, Lai Y.

Drug Metab Dispos. 2012 Feb;40(2):407-11. doi: 10.1124/dmd.111.039297. Epub 2011 Oct 26.

PMID:
22031626
35.

Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration.

Cole S, Bagal S, El-Kattan A, Fenner K, Hay T, Kempshall S, Lunn G, Varma M, Stupple P, Speed W.

Xenobiotica. 2012 Jan;42(1):11-27. doi: 10.3109/00498254.2011.617847. Epub 2011 Oct 4. Review.

PMID:
21970687
36.

Development of a new permeability assay using low-efflux MDCKII cells.

Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, Lai Y, Federico JJ 3rd, Davidson RE, Smith R, Reyner EL, Lee C, Feng B, Rotter C, Varma MV, Kempshall S, Fenner K, El-Kattan AF, Liston TE, Troutman MD.

J Pharm Sci. 2011 Nov;100(11):4974-85. doi: 10.1002/jps.22674. Epub 2011 Jul 15.

PMID:
21766308
37.

Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.

Strick CA, Li C, Scott L, Harvey B, Hajós M, Steyn SJ, Piotrowski MA, James LC, Downs JT, Rago B, Becker SL, El-Kattan A, Xu Y, Ganong AH, Tingley FD 3rd, Ramirez AD, Seymour PA, Guanowsky V, Majchrzak MJ, Fox CB, Schmidt CJ, Duplantier AJ.

Neuropharmacology. 2011 Oct-Nov;61(5-6):1001-15. doi: 10.1016/j.neuropharm.2011.06.029. Epub 2011 Jul 7.

PMID:
21763704
38.

pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.

Varma MV, Rotter CJ, Chupka J, Whalen KM, Duignan DB, Feng B, Litchfield J, Goosen TC, El-Kattan AF.

Mol Pharm. 2011 Aug 1;8(4):1303-13. doi: 10.1021/mp200103h. Epub 2011 Jul 11.

PMID:
21710988
39.

Anxiolytic-like activity of pregabalin in the Vogel conflict test in α2δ-1 (R217A) and α2δ-2 (R279A) mouse mutants.

Lotarski SM, Donevan S, El-Kattan A, Osgood S, Poe J, Taylor CP, Offord J.

J Pharmacol Exp Ther. 2011 Aug;338(2):615-21. doi: 10.1124/jpet.111.180976. Epub 2011 May 10.

PMID:
21558437
40.

Current advances in delivery of biotherapeutics across the blood-brain barrier.

Rajadhyaksha M, Boyden T, Liras J, El-Kattan A, Brodfuehrer J.

Curr Drug Discov Technol. 2011 Jun;8(2):87-101. Review.

PMID:
21513485
41.

Targeting intestinal transporters for optimizing oral drug absorption.

Varma MV, Ambler CM, Ullah M, Rotter CJ, Sun H, Litchfield J, Fenner KS, El-Kattan AF.

Curr Drug Metab. 2010 Nov;11(9):730-42. Review.

PMID:
21189135
42.

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.

Pfefferkorn JA, Litchfield J, Hutchings R, Cheng XM, Larsen SD, Auerbach B, Bush MR, Lee C, Erasga N, Bowles DM, Boyles DC, Lu G, Sekerke C, Askew V, Hanselman JC, Dillon L, Lin Z, Robertson A, Olsen K, Boustany C, Atkinson K, Goosen TC, Sahasrabudhe V, Chupka J, Duignan DB, Feng B, Scialis R, Kimoto E, Bi YA, Lai Y, El-Kattan A, Bakker-Arkema R, Barclay P, Kindt E, Le V, Mandema JW, Milad M, Tait BD, Kennedy R, Trivedi BK, Kowala M.

Bioorg Med Chem Lett. 2011 May 1;21(9):2725-31. doi: 10.1016/j.bmcl.2010.11.103. Epub 2010 Nov 26.

PMID:
21183342
43.

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.

Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.

J Med Chem. 2010 Feb 11;53(3):1098-108. doi: 10.1021/jm901371v.

PMID:
20070106
44.

Diethylation labeling combined with UPLC/MS/MS for simultaneous determination of a panel of monoamine neurotransmitters in rat prefrontal cortex microdialysates.

Ji C, Li W, Ren XD, El-Kattan AF, Kozak R, Fountain S, Lepsy C.

Anal Chem. 2008 Dec 1;80(23):9195-203. doi: 10.1021/ac801339z.

PMID:
19551941
45.

Physicochemical determinants of human renal clearance.

Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.

J Med Chem. 2009 Aug 13;52(15):4844-52. doi: 10.1021/jm900403j.

PMID:
19445515
46.

Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.

Duplantier AJ, Becker SL, Bohanon MJ, Borzilleri KA, Chrunyk BA, Downs JT, Hu LY, El-Kattan A, James LC, Liu S, Lu J, Maklad N, Mansour MN, Mente S, Piotrowski MA, Sakya SM, Sheehan S, Steyn SJ, Strick CA, Williams VA, Zhang L.

J Med Chem. 2009 Jun 11;52(11):3576-85. doi: 10.1021/jm900128w.

PMID:
19438227
47.
48.

Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats.

Merzlikine A, Rotter C, Rago B, Poe J, Christoffersen C, Thomas VH, Troutman M, El-Kattan A.

Drug Dev Ind Pharm. 2009 Sep;35(9):1082-91. doi: 10.1080/03639040902774156.

PMID:
19294548
49.

Oxadiazolone bioisosteres of pregabalin and gabapentin.

Wustrow DJ, Belliotti TR, Capiris T, Kneen CO, Bryans JS, Field MJ, Williams D, El-Kattan A, Buchholz L, Kinsora JJ, Lotarski SM, Vartanian MG, Taylor CP, Donevan SD, Thorpe AJ, Schwarz JB.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):247-50. doi: 10.1016/j.bmcl.2008.10.101. Epub 2008 Oct 25.

PMID:
19010672
50.

Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.

Hurst S, Loi CM, Brodfuehrer J, El-Kattan A.

Expert Opin Drug Metab Toxicol. 2007 Aug;3(4):469-89. Review.

PMID:
17696800

Supplemental Content

Loading ...
Support Center